Jubivilda Tablet SR contains Vildagliptin 100mg, a potent dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for the management of type 2 diabetes mellitus. Vildagliptin enhances glycemic control by increasing the levels of active incretin hormones, which stimulate insulin secretion and suppress glucagon release in a glucose-dependent manner, thereby improving postprandial and fasting blood glucose levels. The sustained-release formulation of Jubivilda ensures a consistent plasma concentration, optimizing therapeutic efficacy and improving patient compliance through once-daily dosing. This medication is recommended as monotherapy in patients inadequately controlled by diet and exercise or as combination therapy with other antidiabetic agents, including metformin, sulfonylureas, or insulin, when glycemic targets are not achieved. Jubivilda Tablet SR is generally well tolerated; however, clinicians should monitor for potential adverse effects such as hypoglycemia, especially when used concomitantly with insulin secretagogues, and rare occurrences of hepatic dysfunction. Regular assessment of renal and hepatic function is advised during therapy. This agent should be used as part of a comprehensive diabetes management plan, including lifestyle modifications. Patients should be counseled on adherence and the importance of routine monitoring to optimize outcomes and minimize complications associated with type 2 diabetes mellitus.